Orphenadrine Citrate Extended-Release Tablets, USP 100 mg, Rx Only, 100 Tablets, Manufactured by Sandoz Inc., Princeton, NJ 08540 NDC 0185-0022-01.
Published April 13, 2022 · Recall initiated: March 21, 2022
Summary
FDA records drug Class II recall D-0753-2022, published April 13, 2022 and initiated March 21, 2022. Recalling firm: Sandoz, Inc; Status: Terminated; Reported quantity: 7908 bottles(790,800 extended release tablets); Lot: Lot #: JX6411, JX6413, Exp. 05/2022 Lot #: KC0723,KC3303, Exp. 08/2022 Lot #: KE4348, KE7169,KE4349, Exp. 11/2022 Lot #: KL3199, KM0072,KS3939, Exp. 03/2023 Lot #: LA7704, LA7703,LA9243, Exp. 11/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations:Nitrosamine impurity (NMOA) above the acceptable daily limit.
What to do
Voluntary: Firm initiated · Press Release
Get an email if ORPHENADRINE CITRATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- ORPHENADRINE CITRATE
- Manufacturer
- Sandoz, Inc
- Distributor
- Nationwide
- Lot
- Lot #: JX6411, JX6413, Exp. 05/2022 Lot #: KC0723,KC3303, Exp. 08/2022 Lot #: KE4348, KE7169,KE4349, Exp. 11/2022 Lot #: KL3199, KM0072,KS3939, Exp. 03/2023 Lot #: LA7704, LA7703,LA9243, Exp. 11/2023
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMethylprednisolone Tablets, USP 4mg, 100-count bottle, Rx Only, Manufactured by: Jubliant CadistaApril 13, 2022
- FDAAccuretic (quinapril HCl/hydrochlorothiazide) Tablets, 10 mg/12.5 mg*, 90 Tablets bottles, Rx Only,April 13, 2022
- FDAThe Natural Dentist Healthy Breath Antiseptic Rinse, Cool Mint, 16.9 FL OZ (500 mL, Manufactured for ReviveApril 13, 2022
- FDAAccuretic (quinapril HCl/hydrochlorothiazide) Tablets 10 mg/12.5 mg 90 tablets bottle, Rx Only, DistributedApril 13, 2022
- FDASucralfate Oral Suspension, USP 1g/10mL, packaged in a) 40 case of 10 mL unit Dose Cups (NDC 69339-148-17) andApril 13, 2022
- FDAOrphenadrine Citrate Extended Release Tablets, 100 mg a)100-count bottle, (NDC 0185-0022-01) b) 1000-countJuly 30, 2014
Questions about this recall
Was Orphenadrine Citrate Extended-Release Tablets, USP 100 mg, Rx Only, 100 Tablets, Manufactured by Sandoz Inc., Princeton, NJ 08540 NDC 0185-0022-01. recalled?
Yes. FDA published recall D-0753-2022 on April 13, 2022. Reported hazard: CGMP Deviations:Nitrosamine impurity (NMOA) above the acceptable daily limit.
What should I do if I have this product?
Voluntary: Firm initiated · Press Release
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: ORPHENADRINE CITRATE.